Cardiac steroids are used to treat various diseases including congestive heart failure and cancer. The aim of this study was to investigate the anti-leukemic activity of UNBS1450, a semi-synthetic cardenolide belonging to the cardiac steroid glycoside family. Here, we report that, at low nanomolar concentrations, UNBS1450 induces apoptotic cell death. Subsequently, we have investigated the molecular mechanisms leading to apoptosis activation. Our results show that UNBS1450 inhibits NF-κB transactivation and triggers apoptosis by cleavage of pro-caspases 8, 9 and 3/7, by decreasing expression of anti-apoptotic Mcl-1 and by recruitment of pro-apoptotic Bak and Bax protein eventually resulting in cell death.
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Introduction
Most anti-cancer drugs are isolated from natural sources or are at least bearing close structural relationships to natural compounds. Both, marine and terrestrial organisms are considered today as important sources for novel lead compounds.
Non-cardiotonic steroid glycosides obtained from the tropical plant Calotropis procera possess anti-cancer potential via binding to the 31 Na + /K + -ATPase isozymes. The cardenolide UNBS1450 ( Figure 1A ) has been analyzed in vitro as well as in vivo on non small cell lung cancer (NSCLC) and glioblastoma xenograft mice models [1, 2] . UNBS1450
is a chemically modified form of 2-oxovoruscharin, a derivative of voruscharin ; despite its already promising anti-cancer potential, the high toxicity of 2-oxovoruscharin required chemical modifications to improve tolerance in vivo [3] . The improved semi-synthetic compound UNBS1450 revealed itself to be significantly less toxic when compared to its mother compound and in the same time was proven to be even more potent in cancer therapy:
with an average MTD of up to 120 mg/kg, chronic administration increased mouse survival and reduced glioblastoma cell migration. Mijatovic et al. showed that UNBS1450-mediated antitumor activity is due to activation of non-apoptotic cell death mechanisms in Na + /K + -ATPase 1 over-expressing glioma cells [4] . UNBS1450 has the capacity to disorganize nucleolar structure and functions via impairment of cyclin-dependent kinase and c-Myc expressions accompanied by disorganization of cancer cell-specific perinucleolar bodies. This non-apoptotic cancer cell death was a new cardenolide-induced mechanism of antitumor action [5] and this drug was described to be able to circumvent glioblastoma resistance to apoptosis [6] .
Nuclear factor (NF)-B has been shown previously to be implicated in (1) cell death (apoptosis), (2) cell adhesion, (3) cell proliferation, (4) innate-and adaptive-immune response and (5) cancer development. This dimeric protein complex can both induce and repress gene expression, by binding to DNA sequences found in promoter and enhancer regions. NF-κB hetero-and homodimers can be constituted of five different family members: RelA (p65),
RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2) [7] . In the absence of an extrinsic cell signal, NF-κB dimers remain sequestered in the cytoplasm, inactivated by the NF-κB inhibitor IB. Upon cell stimulation by cytokines, proliferating agents, carcinogens or physical stress, IB phosphorylation by the Iκ kinase (IKK) frees the NF-κB dimer, then rapidly translocating into the nucleus and transactivating more than 550 genes.
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Deregulation of NF-κB leads to various pathologies including chronic inflammations and cancer [8] . NF-κB has become a major target in drug engineering. To date, a number of natural NF-κB inhibitors are being investigated, many of them being plant-derived isoprenoids and polyphenols.
As NF-κB is responsible for increased cell resistance towards possible cytocidal treatments currently applied in clinics, apoptosis induction through NF-κB inhibition and/or extrinsic and intrinsic pathway activation is considered as a main aim in cancer research.
Apoptosis induction through NF-κB inhibition and subsequent extrinsic and intrinsic cell death pathway activation is considered a main target in cancer research. During apoptosis induction, many different activation cascades eventually lead to caspase-3 or -7 cleavage and subsequent cell death [9] .
In the absence of concluding investigations of anti-cancer effects of UNBS1450 in human leukemia cells, we hereby analyzed the effect of UNBS1450 on activation of cell death mechanisms and NF-κB pathway inhibition in human leukemia cells and demonstrate for the first time that nanomolar concentrations of UNBS1450 induce canonical apoptotic cell death mechanisms.
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Material and Methods

Compounds and purification
TNFα was purchased from Sigma-Aldrich (Bornem, Belgium) and dissolved to a concentration of 10 mg/mL in PBS 1X supplemented with 0,5 % (w/v) BSA according to the manufacturer's instructions.
UNBS1450 was a gift of Unibioscreen (Pr Robert Kiss, Brussels, Belgium): the compound, with a molecular weight of 605.8g and received as dry powder, was solubilized in 52.95 % DMSO (Sigma-Aldrich, Bornem, Belgium) and then further diluted to 5 % DMSO/95 % H 2 0 to get working aliquots with a concentration of 5 mM. Both were frozen at -20 °C. Control cells were treated with equivalent amounts of DMSO.
Cell culture
K562 (human chronic myelogenous leukemia), U937 (histiocytic lymphoma), Jurkat Healthy blood samples were kindly donated as buffy coats by the Red Cross (Luxembourg, Luxembourg). By applying diluted (1/3) blood onto a Ficoll layer followed by centrifugation (400 g, 20 min), mononuclear cells were isolated and collected. The isolated peripheral blood mononuclear cells (PBMC) were kept in culture at 37 °C and 5 % CO 2 for 24 h before they were subjected to treatments.
Electrophoretic mobility shift assay (EMSA)
Both, K562 and Jurkat cells, cultured in growth medium (RPMI, 10 % FCS) at a concentration of 3*10 5 cells/mL, were pre-treated or not for 2 h with UNBS1450 respectively at 40 nM and 20 nM before being activated by TNFα (20 ng/mL) for 6 h. Cells were then harvested and washed twice in PBS 1X; supernatants were discarded and cell pellets were stored overnight at -80 °C. Nuclear protein extractions were performed as described 6 previously before being stored at -80 °C [10] . The oligonucleotide NF-κBc (consensus NF-κB site) (Eurogentec, Liège, Belgium) (5'-AGTTGAGGGGACTTTCCCAGGC-3') and its complementary sequence were used as probe. After being hybridized, the probes were radiolabelled using [g-32 P]ATP (MP Biomedicals, Illkirch, France) and the EMSA assay was realized according to conditions established before [10] .
Transient transfection and luciferase reporter gene assay
K562 and Jurkat cells were transiently transfected as described previously [10] . 
Cell viability assessment
Percentages of cell survival were evaluated using Promega's CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Leiden, Netherlands) kit, according to manufacturer's instructions. Alternatively, Trypan Blue staining was used to determine cell integrity. Data were normalized to the control and reported as percentage of viable cells.
Analysis of apoptosis
Analysis of nuclear fragmentation. Percentages of apoptotic cells, quantified as the fraction of apoptotic nuclei, were assessed by fluorescence microscopy (Leica-DM IRB 
Extraction of cellular proteins
After indicated incubation times with UNBS1450 and TNFα, K562, U937 and Jurkat cells were lysed; nuclear and cytoplasmic extracts were prepared according to [10] .
RT-PCR Analysis
Isolation of total RNA was performed using a NucleoSpin® (Macherey-Nagel, Hoerdt, France) kit. 1 g of total RNA were submitted to reverse transcription (RT) using Oligo(dT) primers (SuperScript First-Strand Synthesis System, Invitrogen, Fisher Scientific, Tournai, Belgium). The resulting RT products were used as templates for PCR amplification using SYBR ® Green (Power SYBR Green PCR Master mix 1X, Applied Biosystems, Halle, Belgium) and Na + /K + -ATPase -subunit mRNA specific primers (F : 5'-CTA-CCT-GGC-
Belgium). The amount of cDNA synthesized was evaluated by amplification of the GAPDH gene (F : 5'-ACA-GTC-AGC-CGC-ATC-TTC-TT-3' ; R : 5'-ACG-ACC-AAA-TCC-GTT-GAC-TC-3') (Eurogentec, Liège, Belgium) as a standard. After amplification, the PCR products were separated on a 2 % agarose gel. M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
Western Blot analysis
Statistical analysis
Data is expressed as mean + -S.D. and its signification degree was analyzed by Student's T-tests. P-values below 0,05 were considered as statistically significant.
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Results
UNBS1450 induces apoptosis in human leukemia cells
We first evaluated the effect of UNBS1450 on the cell growth of chronic myeloid leukemia K562, histiocytic lymphoma U937 and acute T-cell leukemia Jurkat human leukemia. Cells were treated for 24, 48 and 72h with different concentrations of UNBS1450
and their culture concentrations estimated by Trypan Blue exclusion assay. As reported in Figure 1B , UNBS1450 deeply affected cell growth in a dose-dependent manner with an IC 50 value of 13.37±2.1nM in U937.
To disentangle whether the effects of UNBS1450 were due to an impact on cell viability rather than an effect on cell metabolism and, therefore growth, we performed at first a cell cycle analysis to detect and quantify the presence of any sub-G1 phase. The analysis reported in Figure 1C showed that UNBS1450 lead to accumulation of cells in a sub-G1
phase in a dose-dependent manner, significantly starting from 15nM, thus confirming that UNBS1450 induced cell death. From 20nM to 30nM, UNBS1450 increasingly drove U937 cells into a sub-G1 phase ( Figure 1C) .
Next, we investigated the nature of cell death induced by UNBS1450, first by analyzing alterations in cell morphology by Hoechst staining and fluorescence microscopy ( Figure 1D, top) . As shown, the nuclei of U937 cells treated with UNBS1450 underwent morphological alterations typically occurring during apoptosis [11] . Figure 1D (bottom) shows the quantification of apoptosis after UNBS1450 treatment, as estimated by counting the fraction of cells stained with Hoechst and presenting fragmented nuclei. Annexin V/PI double staining confirmed apoptotic cell death ( Figure 1E ) starting from 15nM, thus giving similar results to Hoechst analysis.
In order to generalize our effects, we used K562 cells and observed similar findings.
Again, UNBS1450 reduced cell proliferation in a dose-and time-dependent manner with an IC 50 value of 32.65±3.10nM at 48 h (Supplemental Figure 1A) . Cell cycle analysis (Supplemental Figure 1B) showed that an incubation time of 48 h in the presence of UNBS1450 50nM drove a fraction of cells into a sub-G1 phase while overall cell status remained rather unchanged; G1 and G2/M phases still showed control-comparable patterns.
Hoechst staining indicated fragmented cell nuclei of cells dying via apoptosis (Supplemental Figure 1C) . FACS analysis for the exposure of phosphatidylserine/plasma membrane integrity by annexin V/PI analysis confirmed the activation of an apoptotic program A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 (Supplemental Figure 1D) . Similar effects of UNBS1450 on cell death induction were observed in Jurkat T cells (Supplemental Figures 2A and B) .
Concerning the specificity of UNBS1450 for cancer cells, we further analyzed the effects of UNBS1450 on normal, healthy PBMCs ( Figure 1F) . Figure 1D ).
As it has been shown that the 1 subunit of Na+/K+-ATPases is a target for UNBS1450 [2] and that it is frequently overexpressed in solid tumor cells where UNBS1450
is severely inhibiting proliferation 
Effect on anti-apoptotic cell signaling pathways
We subsequently investigated whether UNBS1450 was able to trigger a caspasedependent apoptotic cell death ( Figure 3A) . To this purpose, a kinetic analysis (0h to 24h) was performed on U937 cells treated with UNBS1450 at 20nM. We demonstrated that UNBS1450 at 20nM induced the cleavage of the pro-caspases-9 and -8 starting after 12h of incubation time. The executor pro-caspases-3 and-7, substrates of caspase-9, were cleaved into active caspase-3 and 7 ( Figure 3A) .
Induction of apoptosis can be triggered by both inhibition of anti-apoptotic-and/or by activation of pro-apoptotic mechanisms. Here, overall expression of XIAP and Bcl-2 were not influenced by UNBS1450 (Figure 3B) . The expression level of Mcl-1 however, another antiapoptotic Bcl-2 family member, was sensibly affected by the treatment with UNBS1450 as a
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Activation of pro-apoptotic mechanisms
We then analyzed in situ the activation status of pro-apoptotic Bak and Bax in U937 cells, untreated and treated with 10 to 30 nM of UNBS1450, by using antibodies specifically recognizing activated forms of both pro-apoptotic Bcl-2 family members. Immunostained cells were counterstained with Hoechst to detect apoptotic nuclei. Bak resulted activated by treatments with 15 nM UNBS1450 and higher ( Figure 4A) . Similar results were observed for activated Bax (Bax6A7) ( Figure 4B ). As expected, both activated Bak and Bax co-localized with cells presenting fragmented, apoptotic nuclei, witnessing apoptotic cell death triggered by UNBS1450 a semi-synthetic cardenolide originally from the plant Calotropis Procera.
Inhibition of NF-κB pathway activation
NF-κB transcription factor is well known to act as an inhibitor of apoptotic cell signaling specifically via transactivation. Moreover Mijatovic et al. [12] already provided first insights into UNBS1450-induced inhibition of NF-κB activation. Here we observed that UNBS1450 reduced TNFα-driven NF-κB activation in a dose-dependent manner in K562 and
Jurkat cells (Figure 5A and B). As illustrated in Table I , UNBS1450 has however no repressing effect on constitutive, basal NF-B activity in K562 cells.
In order to further confirm the inhibitory effect of UNBS1450 on the TNFα-induced NF-κB signaling pathway, we realized EMSA. Figure 5C clearly shows that at a concentration of UNBS1450 40 nM inhibits TNFα-induced NF-κB-DNA binding. By applying various pre-treatment times from 0 to 16 h, we obtained a complete inhibition after 8 h of pre-incubation. Incubation with p50 and p65 antibodies enabled us to identify the NF-κB dimer composition as p50 and p65. Similar results were obtained for Jurkat cells (Figure 5D ).
NF-κB activation is generally initiated by the degradation of its natural inhibitor IκBα;
we thus assessed IκBα integrity as well as the translocation of p65 from the cytoplasm to the nucleus by Western Blot analysis ( Figure 5E ). Both degradation of IκBα as well as translocation of p65 into the nucleus, were analyzed by Western Blot. In control cells without UNBS1450 pre-treatment, IκBα degradation was observed after 10 min of TNFα stimulation;
consequently, p65 translocation to the nucleus was observed in parallel. In contrast, the presence of UNBS1450 inhibited TNFα-induced degradation of IκBα and considerably prevented the translocations of p65 into the nucleus ( Figure 5E , right panel).
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To further investigate the influence of UNBS1450 on downstream NF-κB signaling in K562, U937 and Jurkat cells, we chose IL-8 as it was described that this gene product is under the control of NF-κB. We observed that UNBS1450-pre-treated cells produced significantly lower quantities of IL-8 (less than 600 pg/mL) compared to TNFα only activated K562 cells (1300 pg/mL) ( Figure 5F ). Similar results were obtained for U937 ( Figure 5G) . We also analyzed the impact of UNBS1450 on leukemia cell survival capacity. As finally indicated by increased Annexin V/PI staining, fragmented nuclei after Hoechst staining and thus reduced cell numbers, UNBS1450 is beneficial to an apoptosis induction.
We observed that nanomolar concentrations of UNBS1450 were able to induce the cleavages of the initiator caspases 8 and 9 as shown by Western Blot. Furthermore, we obtained a cleavage induction of the pro-caspase-7, leading to hypothetic thoughts that UNBS1450 might induce apoptosis by processing and concomitant activation of effector caspases such as caspase-7 and caspase-3. Consequently, we assessed expression levels of various Bcl-2 family proteins in order to conclude on a possible amplification of the death signal through activation of the intrinsic mitochondrial cell death pathways [13] [14] . The analysis of cell proliferation in the presence of UNBS1450 in both cell lines investigated reveals that the compound is able to affect cell proliferation at concentrations lower than those requested to induce apoptosis (see Figure 1B and supplemental Figure 1A ). This is in line with previous findings [15] and prompts to elucidate in the future whether this cytostatic potential may be also implicated in determining the cytotoxic effect.
Several studies underline their pivotal role [16] in apoptosis induction [17, 18] [19].
Loss of expression as well as over-expression of Bcl-2 family genes, depending on the pro-or anti-apoptotic potential, can lead to oncogenesis by decreased malignant cell death. It is for instance known that over-expression of anti-apoptotic Bcl-2 or Mcl-1 disables apoptosis A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 As a conclusion, we hereby further described the mechanism by which UNBS1450
inhibits tumor expansion by cell death induction. As an addition to existing knowledge of anti-cancer activities of UNBS1450 due to autophagy [4] [5] mainly on human glioblastoma
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